Table 1.

Current completed phase I and II clinical trials on stem cell and ischemic stroke.

Stem cell completed clinical trials for ischemic stroke
Authors	NCT	Stage of trial	Type of stem cells used/mode of delivery	Primary outcomes	Results
Kalladka et al. 2016 [9]	01151124	Phase I	NSCs: CTX-DP drug product/stereotactic ipsilateral putamen injection	Incidence of adverse events	No adverse events were seen NIHSS improvement ranged from 0–5 (secondary outcome)
Qiao et al. 2014 [69]	NA	Phase I	Cotransplantation with neural stem/progenitor cells and mesenchymal stromal cells/IV	Safety and feasibility	No evidence of neurological deterioration or neurological infection
Prasad et al. 2014	02425670	Phase II	BM mononuclear cells/IV	Functional ability-modifiedBarthel Index score	No significant difference between BMSC versus control in Barthel Index score
Banerjee et al. 2014	00535197	Phase I	CD34+ stem cells/intra-arterial	Safety	Safe and feasible
Savitz and Sean 2014	00859024	Phase I	Autologous mononuclear bone marrow cells/IV	Adverse events	No study-related adverse events

IV: intravenous; BMSC: bone marrow stem cells; NIHSS: National Institute of Health Stroke Scale; NCT: National Clinical Trial Number.